Gene therapy experts and advocates warning of the sector’s many challenges found a receptive audience in FDA leadership at a ...

Late-stage results Otsuka presented in IgA nephropathy triggered a sell-off in Vera shares. Elsewhere, investors scrutinized ...

A deal worth up to $712 million with the China-based biotech gives Cullinan T cell engagers aimed at BCMA and CD19, two ...

The agency has provided only limited details about its AI pilot as it advances an “aggressive timeline” for the tool's ...

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...

The investment bank says funding was down 57% last month, to $2.7 billion, and argues the new administration’s FDA ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Elinzanetant proved effective for managing disruptive vasomotor symptoms in women on endocrine therapy, supporting a Bayer ...

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate ...